Sol-Gel Technologies Ltd. (SLGL) touched a new 52-week high of $18.66 yesterday, reflecting growing investor confidence. With a key clinical trial milestone on the horizon, it will be worth watching whether the stock's upward momentum can be sustained.
This dermatology company focuses on skin diseases for which there are no approved therapeutics. It has successfully developed two FDA-approved products, EPSOLAY and TWYNEO, and is advancing two drug candidates in clinical development: SGT-610 (topical Patidegib) and SGT-210 (topical Erlotinib).
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.